Immune Cell Signal Reveals How Triple Therapy Reshapes Liver Tumors

A combination treatment for advanced liver cancer appears to do something remarkable inside the tumor itself: it helps build the biological equivalent of lymph nodes, right where the cancer lives. A new study published in the Journal of Translational Medicine reports that patients with unresectable hepatocellular carcinoma who received a triple regimen of transarterial chemoembolization, the kinase inhibitor lenvatinib, and an anti-PD-1 immunotherapy antibody developed far denser and more mature intratumoral tertiary lymphoid structures than comparable patients who went straight to surgery. These structures, often abbreviated TLSs, are organized clusters of immune cells that can form in chronically inflamed tissue and are increasingly recognized as sites where the body mounts a targeted attack against cancer. The findings offer one of the most detailed mechanistic pictures yet of how a widely used combination therapy may reprogram the tumor microenvironment, and they point to a chemokine-driven dialogue between two specialized immune cell types as the engine behind that transformation.

The research team, led by investigators at the Shengli Clinical Medical College of Fujian Medical University and collaborating institutions in China, focused on a clinically challenging population: patients whose hepatocellular carcinoma could not be removed surgically at diagnosis. For these individuals, the standard of care increasingly involves locoregional treatments such as transarterial chemoembolization, or TACE, in which chemotherapy is delivered directly into the tumor’s arterial supply and the vessel is blocked to starve the tumor of blood. When TACE is paired with lenvatinib, an oral drug that suppresses the tumor’s blood vessel formation, and with antibodies that block the programmed death-1 checkpoint, the resulting triple therapy has shown encouraging response rates without severe adverse events. What remained unclear was precisely how these three very different interventions cooperate at the cellular level to convert a tumor that once resisted immune attack into one that appears to organize its own immune defenses.

To investigate, the researchers enrolled patients with unresectable hepatocellular carcinoma who underwent salvage surgical resection after receiving triple therapy and who achieved at least a partial pathological response. Because fine-needle aspiration biopsies taken before treatment cannot reliably capture the architecture of tertiary lymphoid structures, no true pre-treatment tissue was available for direct comparison. The team instead assembled a matched comparator cohort of specimens from patients treated with upfront surgery without any prior therapy, matching each pair one-to-one by propensity score on age, sex, etiology, Barcelona Clinic Liver Cancer stage, and maximum tumor diameter, yielding 62 specimens per group. The authors are careful to note that this design is cross-sectional and between-patient rather than longitudinal within the same individual, an important caveat when interpreting the associations. Patients who achieved a pathological complete response were excluded because the extensive necrosis left behind after treatment would have made assessment of the immune microenvironment impossible.

The results were striking. Tertiary lymphoid structures were identified in 93.5 percent of the post-treatment specimens, 58 of 62, compared with 59.6 percent of the comparator specimens, 37 of 62. More telling was the density: within the tumor itself, the post-treatment cohort averaged 0.216 plus or minus 0.125 TLS per square millimeter, versus just 0.028 plus or minus 0.046 in the untreated comparison group, a difference that was highly statistically significant. Intriguingly, the density of peritumoral TLSs, those located in the surrounding liver tissue rather than inside the tumor, did not differ between the groups, at 0.020 versus 0.022 TLS per square millimeter. This spatial specificity suggests that the triple therapy acts locally within the tumor bed, where the combined effects of embolization-induced tissue damage, lenvatinib-mediated vascular remodeling, and checkpoint blockade may create the inflammatory conditions needed for these immune aggregates to assemble inside the malignancy itself.

The study went beyond simply counting structures and examined their maturity, a critical distinction in TLS biology. Early tertiary lymphoid structures are loose aggregates of lymphocytes, while more mature forms develop organized follicles resembling those found in lymph nodes, complete with germinal centers where B cells proliferate, mutate their antibodies, and refine their specificity. The researchers classified the structures into early TLSs, primary follicle-like TLSs, and secondary follicle-like TLSs, the latter representing the most developed stage. Their analysis showed that intratumoral TLS density was positively correlated with maturation, meaning that tumors with more structures also tended to harbor more developed ones. This matters because mature, germinal center-bearing TLSs are thought to support more effective and durable anti-tumor immunity, potentially including the generation of B cells capable of recognizing tumor antigens.

Clinically, the findings carried weight. Of the 62 patients who underwent salvage resection, 41, or 66 percent, achieved a major pathological response, defined as substantial residual tumor destruction. The team found that higher intratumoral TLS density and greater TLS maturity were associated with pathological response and with longer relapse-free survival and overall survival. While the study’s design cannot prove that the TLSs caused the better outcomes, the correlation aligns with a growing body of literature across multiple cancer types linking these structures to favorable prognosis and improved responses to immunotherapy. The authors propose that intratumoral TLS density and maturity could serve as candidate biomarkers for stratifying patients after salvage resection, helping clinicians identify who may benefit most from continued surveillance or additional therapy.

To dissect the cellular machinery behind TLS formation, the researchers turned to single-cell RNA sequencing on ten tumor samples, a technique that profiles gene expression in individual cells and allows researchers to identify distinct cell populations within a complex tissue. The analysis revealed that tumors from patients treated with triple therapy contained higher proportions of two specialized immune cell populations: CXCL13-positive T follicular helper cells and CXCR5-positive germinal center B cells. T follicular helper cells are the conductors of the adaptive immune system’s humoral response, guiding B cells within germinal centers to produce high-quality antibodies. CXCL13, a chemokine, is one of their signature products, and CXCR5 is its receptor on B cells. Ligand-receptor analysis of the single-cell data indicated stronger CXCL13-CXCR5 signaling between these two populations after triple therapy, suggesting that the treatment amplifies a communication channel that is central to lymphoid tissue organization.

From these observations, the authors propose a mechanistic model. In their framework, triple therapy increases the abundance and activity of T follicular helper cells within the tumor, which in turn secrete more CXCL13. This chemokine gradient then recruits CXCR5-expressing germinal center B cells into the tumor, and the concentrated interaction between the two cell types supports the assembly and progressive maturation of intratumoral tertiary lymphoid structures. In essence, the therapy may be seeding the tumor with the cellular ingredients and chemical signals that lymphoid organs use during their own development, allowing an immune training ground to take shape in a place where the body normally tolerates or ignores the malignancy. The model is presented as a hypothesis consistent with the observed data rather than a definitively proven causal pathway, reflecting the correlational nature of the study.

The technical rigor of the work deserves attention. The researchers combined immunohistochemistry, which uses antibodies to visualize specific proteins in tissue sections, with multiplex immunofluorescence, which allows several markers to be detected simultaneously and preserves the spatial relationships between cell types. Single-cell transcriptomics added an unbiased molecular layer, and the team employed computational tools such as area-under-the-curve cell scoring and dimensionality reduction methods to characterize cell states. Balance between the matched cohorts was verified using standardized mean differences, a statistical approach that guards against confounding when comparing groups. The study was conducted under the Declaration of Helsinki with ethics approval from Fujian Provincial Hospital, and participants provided informed consent. The authors declared no competing financial interests, and the funders, which included provincial science foundations and health commission projects in Guangxi and Fujian, had no role in study design, data analysis, or reporting.

For the field of hepatocellular carcinoma, one of the most lethal and heterogeneous human cancers, the study adds an important piece to the puzzle of why combination regimens work when their individual components sometimes do not. It also highlights a broader theme in modern cancer immunology: the tumor microenvironment is not a passive backdrop but a dynamic ecosystem that can be pushed toward an organized, memory-generating immune architecture. If future studies validate intratumoral TLS density and maturity as predictive biomarkers, pathologists could one day examine a resected specimen and use these features to guide decisions about adjuvant therapy. And if the CXCL13-CXCR5 axis proves to be the pivotal lever, it may represent a target for interventions designed to build or strengthen tertiary lymphoid structures in tumors that currently lack them, extending the benefits of immunotherapy to patients whose cancers have so far remained immunologically silent.

Subject of Research: CXCL13-positive T follicular helper cells and tertiary lymphoid structure formation in unresectable hepatocellular carcinoma treated with triple therapy

Article Title: Intratumoral CXCL13 + T follicular helper cells are associated with the formation and maturation of tertiary lymphoid structures in unresectable hepatocellular carcinoma treated with triple therapy

Article References: Intratumoral CXCL13 + T follicular helper cells are associated with the formation and maturation of tertiary lymphoid structures in unresectable hepatocellular carcinoma treated with triple therapy. (n.d.). https://doi.org/10.1186/s12967-026-09031-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09031-y

Keywords: hepatocellular carcinoma, tertiary lymphoid structures, CXCL13, T follicular helper cells, CXCR5, triple therapy, transarterial chemoembolization, lenvatinib, anti-PD-1, tumor microenvironment, single-cell RNA sequencing, immunotherapy